Caribou Biosciences, Inc. (CRBU) Stock

Caribou Biosciences, Inc. (CRBU) is a Healthcare stock trading at $1.64 (as of 2026-06-18), with a market capitalization of $234.07M and a trailing P/E of -1.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Caribou Biosciences develops genome-edited, allogeneic cell therapies, including CAR-T and CAR-NK candidates, aimed at treating hematologic malignancies and solid tumors in the United States and internationally. Its programs include CB-010 for relapsed/refractory B-cell non-Hodgkin lymphoma, CB-011 for relapsed/refractory multiple myeloma, CB-012 for relapsed/refractory acute myeloid leukemia, and CB-020 for solid tumors.

Valuation — source: SEC EDGAR (first-party)
Price	$1.64
Market Cap	$234.07M
P/E Ratio	-1.2
EV / EBITDA	-1.2
Price / Book	1.59
Price / Sales	14.52
DCF Value (model)	$-19.66
DCF Upside vs Price	-1298.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$11.16M
Net Margin	-1327.4%
Return on Equity	-130.6%
Current Ratio	6.22
Revenue Growth (YoY)	11.7%
EPS Growth (YoY)	-3.6%
FCF Growth (YoY)	-21.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-4.88 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-105.5%
vs Industry	-106.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Pfizer Inc ($8.35M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Rachel E. Haurwitz
Employees	147
Country	US
IPO Date	2021-07-23

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.